Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 294 participants.

Also called NCT01940965

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 294 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01940965
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01940965. Non-randomized; no masking; primary purpose treatment. Start 2013-09 (registry gives no type); primary completion 2015-07 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
lixisenatide AVE0010
Intervention (Drug)
biguanide
Intervention (Drug)
TZD
Intervention (Drug)
alpha-GI
Intervention (Drug)
glinide
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct01940965
Content hash
44d7677079908946f34cb3048c59d909305bc6a9f2ee7ef556fef03476af2d16